News

UVA teaming up with Charlottesville pharmaceutical company for new burn treatment

CHARLOTTESVILLE, Va. (WVIR) – The University of Virginia School of Medicine is teaming up with a Charlottesville company to create a new burn treatment.

Typically when skin is burned, the area surrounding it is impacted and dead, too. This new treatment is a cream that is put directly on severe wounds.

“Our hope is that by doing this, we can actually limit the amount of skin grafts people have to get and be able to treat especially like warfighters,” Doctor Mark Roeser said.

Roeser says the idea behind the drug comes from a type oflung treatment that is usually given in an IV. That form, however, is not convenient to treat burns.

“The time of injury is obviously the part of when you want to get the medication on you,” Roeser said. “So if it’s in a cream form, we can apply it more rapidly.”

Roeser is working with Charlottesville-based pharmaceutical company, Purnovate, which is a subsidiary of Adial, to make that happen.

“We’ve already done work to determine that our drugs seem to work well in skin penetration,” Adial CEO William Stilley said.

Stilley says his company has a history of working with UVA, which is why he and Roeser are taking this next step together.

“He’s going to take our molecules, put them into a cream, and then use them use that to try to develop something that would help him promote healing,” Stilley said.

“This will keep the burns limited to only the part, or at least try to limit to only the part that’s injured and not the part that your body enters either accidentally, or for whatever reason your body does that,” Roeser said.

The cream is supposed to reduce inflammation on burns.

“So much of the body’s damage can be caused by inflammation,” Stilley said. “And if we can have a good anti-inflammatory, there’s a number of different important diseases we can really help.”
The teams think if this works, it could be applied to other wounds, and be used in places where quick treatment counts, like war zones.

Read more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and